Carfilzomib
Status | Pipeline |
Therapeutic cat. | Oncology |
Polymorphic form | Amorphous |
CAS No. | 868540-17-4 |
Reference Product | |
Injectable Form | |
EU DMF readiness | |
CEP | |
CHINESE DMF | |
JAPANESE DMF | |
KOREAN DMF | |
CANADIAN DMF | |
CADIFA | |
US DMF readiness | |
OEB No. | 4 |
Samples | available |
Drug description
Carfilzomib is a type of chemotherapy drug called a proteasome inhibitor. It is used alone or in combination with other medications to treat a blood cancer called multiple myeloma. People with multiple myeloma have abnormal plasma cells, which are a type of white blood cell found in your bone marrow that secrete antibodies (immunoglobulins). These antibodies are protective proteins that help fight infection. When plasma cells become cancerous they grow out of control and make an abnormal antibody. Carfilzomib works by inhibiting the growth of myeloma cells and encouraging them to self-destruct. Myeloma cells use proteasomes to break down proteins within them. Carfilzomib blocks the action of proteasomes, causing the proteins to build up inside the cells and the cells to die. Carfilzomib was approved by the US Food and Drug Administration (FDA) in 2012. It is a second generation proteasome inhibitor that was designed to overcome toxicity and resistance issues that some patients experienced with an older proteasome inhibitor called bortezomib (Velcade). Carfilzomib is available under the brand name Kyprolis. A generic version is also available.
Polpharma API
- Samples available
- OEB 4
- Under development
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).